Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$-2.56
EPS est.
$-2.91
EPS surprise
+12.03%
1-day move
+2.04%
GRAIL, Inc. reported a wider loss than expected on a per-share basis, which may raise concerns among investors. However, the stock still reacted positively, gaining 2.04% on the day. This increase could indicate that investors are focusing more on the EPS surprise rather than the lack of revenue figures.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.56 | $-2.45 | +12.03% |
| Revenue | N/A | $44M | N/A |
No transcript is on record, and the analysis is based on numerical results only.
GRAIL, Inc. is a biotechnology company focused on early cancer detection through innovative blood tests. As part of the health care sector, its work is crucial in improving cancer outcomes and reducing treatment costs.
Last quarter
In Q1-2026, GRAIL reported an EPS of $-2.29, beating estimates by 23.67%. The stock reacted negatively, declining by 2.26% the following day.
Management promises and guidance
EPS beat streak
7Q
EPS beat rate
88%
Avg EPS surprise
+20.18%
Avg 1-day reaction
+1.51%
Analysts expect GRAIL to report a loss this quarter, but there is cautious optimism about revenue growth. The company has consistently beaten EPS estimates in recent quarters.
Bull case
If GRAIL continues its trend of beating EPS estimates, it could signal strong demand for its products and lead to a positive stock reaction.
Bear case
A failure to meet revenue expectations could raise concerns about market acceptance and future growth, leading to a negative stock reaction.
Key metrics to watch
EPS
$-2.45Earnings per share is a key indicator of profitability and can influence investor sentiment.
Revenue
$44MRevenue figures provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will GRAIL achieve revenue of at least $44M this quarter?
Meeting or exceeding this revenue target will be crucial for demonstrating market demand and growth potential.
Q2
How will management address the ongoing losses indicated by the EPS forecast?
Investors will be keen to hear strategies for reducing losses and improving profitability moving forward.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The consensus may underestimate GRAIL's potential for revenue growth due to its innovative product offerings and recent market expansion efforts.
Supporting evidence
GRAIL has consistently beaten EPS estimates, indicating stronger-than-expected performance.
The options market is pricing a larger move than historical averages, suggesting heightened expectations.
Recent trends in early cancer detection may drive increased demand for GRAIL's products.
Key risk
If GRAIL's revenue exceeds $44M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around GRAIL's ability to generate revenue growth while managing its losses.
Bull confirmed if
Revenue exceeding $44M and a narrower EPS loss than expected would confirm the bull case.
Bear confirmed if
Revenue falling below $42M or a wider EPS loss than $-2.98 would confirm the bear case.
What the market is pricing for the move.
Implied Move
±18.37%
Historical Avg
±4.9%
The options market is pricing in a significant move, suggesting that investors anticipate volatility around the earnings report.
Options are pricing ±18.4% while GRAL has averaged ±4.9% over the last 8 prints — setup is pricing rich.
ATM IV
1.0%
30d HV
69.2%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$4.6M
31,492 sh
2 insiders
Net
$4.6M
Net selling
Most Active Insiders· 2 open-market trades
$3.5M
Net selling
Likely market behavior by outcome. Not investment advice.
Beat & raise
If GRAIL beats expectations, history suggests a positive stock reaction, averaging a +1.90% move on such beats.
In line / cautious
If results are in line with expectations, the stock may see muted movement as investors await clearer guidance.
Miss
A miss could lead to a significant downside, with historical data suggesting an average decline when expectations are not met.
The lines on the call that would change the story.
$1.2M
Net selling
Recent Transactions
Oct 5, 2026 · @ $146.39
23,619 sh
$3.5M
Oct 5, 2026 · @ $146.39
7,873 sh
$1.2M
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.